Irreversible Lung Transformation Resulting from Damage In COVID-19 — Discourses and Examples of CT Images
https://doi.org/10.20514/2226-6704-2022-12-5-370-379
Abstract
The problem of the formation of irreversible residual changes after suffering viral lung damage with COVID-19 (COronaVIrus Disease 2019) after two years of the pandemic remains important and discussed. This is due to a large number of patients who have had a coronavirus infection (including those with a large amount of lung damage) and a possible unfavorable prognosis with a decrease in the quality and life expectancy. Given the fact that antifibrotic therapy has recently been actively used for a number of interstitial lung diseases (with idiopathic pulmonary fibrosis and systemic diseases), the question of the possible use of these drugs in case of an unfavorable outcome of COVID-19 is being considered. However, it is still not known exactly how often fibrosis develops in the outcome of a new coronavirus infection, and groups of patients who may have a poor prognosis in the form of an outcome in fibrosis have not been clearly identified.
The review considers the pathogenetic aspects of the possible development of irreversible changes in patients with COVID-19, predisposing factors, as well as diagnostic features with an emphasis on CT scan with the authors’ own observations.
About the Authors
A. S. Vinokurov
Pirogov Russian National Research Medical University; Demikhov City Hospital of Moscow City Health Department; Moscow Multidisciplinary Clinical Center «Kommunarka» of Moscow City Health Department
Russian Federation
Competing Interests:
Russian Federation
Anton S. Vinokurov
Moscow
Competing Interests:
The authors declare no conflict of interests
A. L. Yudin
Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
The authors declare no conflict of interests
References
1. Samsonova M.V., Chernyaev A.L., Omarova Z.R. et al. Features of pathological anatomy of lungs at COVID-19. Pulmonologiya. 2020; 30(5): 519–532. DOI:10.18093/0869-0189-2020-30-5-519-532 [In Russian].
2. Thille A.W., Esteban A., Fernandez-Segoviano P. et al. Chronology histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med. 2013; 1: 395–401.
3. Vasarmidi E., Tsitoura E., Spandidos D.A. et al. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Experimental and therapeutic medicine. 2020; 20: 2557–2560. DOI:10.3892/etm.2020.8980.
4. Carsana L., Sonzogni A., Nasr A. et al. Pulmonary post-morten findings in a series of COVID-19 cases from northern Italy: A two-center descriptive study. Lancet Infect Dis. 2020; 1473-3099(20): 30434–30435.
5. Mohamed Ali R.M., Ibrahim Ghonimy M.B. PostCOVID-19 pneumonia lung fibrosis: a worrisome sequela in surviving patients. Egyptian Journal of Radiology and Nuclear Medicine. 2021; 52: 101. DOI:10.1186/s43055-021-00484-3.
6. Udwadia Z.F., Koul P.A., Richeldi L. Post-COVID lung fibrosis: the tsunami that follow the earthquake. Lung India. 2021; 38: 41–47.
7. Bazdyrev E., Rusina P., Panova M. et al. Lung fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals. 2021; 14: 807. DOI:10.3390/ph14080807.
8. Aronson K.I., Podolanczuk A.J. Lung after COVID-19: Evolving knowledge of post-COVID-19 interstitial lung disease. Ann Am Thorac Soc. 2021; 18(5): 773–779. DOI:10.1513/AnnalsATS.202102-223ED.
9. Leshchenko I.V., Glushkova T.V. Development of fibrosis and impairment of lung function in patients with a new coronavirus disease. Pulmonologiya. 2021;31(5):653–662. DOI:10.180093/0869-0189-2021-31-5-653-662 [In Russian].
10. Ademola S. Ojo, Simon A. Balogun, Oyeronke T. Williams et al. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulmonary medicine. 2020: 6175964. DOI:10.1155/2020/6195964.
11. Chernyaev A.L. Lung atelectasis. Cellular biology of the lungs in normal and pathological conditions, ed. Erokhin V.V., Romanova L.K. M, Medicine. 2000; 383–385. [In Russian].
12. Vinokurov A.S., Zyuzya Yu.R., Yudin A.L. Evolution of follow up CT signs in patients with COVID-19 in early stage. Diagnostic radiology and radiotherapy. 2020; 11(2): 76–88. DOI:10.22328/2079-5343-2020-11-2-76-88 [In Russian].
13. Wu X., Liu X., Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respitatory outcomes in patients following COVID-19-related hospitalization: A prospective study. Lancet Respir. Med. 2021; 9: 747–754.
14. Qin W., Chen S., Zhang Y et al. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. Eur. Respir.J. 2021; 58(1): 2003677. DOI:10.1183/13993003.01217-2020.
15. Zaitsev A.A., Savushkina O.I., Chernyak A.V. et al. Clinical and functional characteristics of patients who recovered from the novel coronavirus infection (COVID-19). Practical Pulmonology. 2020; 1: 78–81 [In Russian].
16. Grekov I.S., Grushina M.V. Fibroproliferative lung changes in the post-epidemic period COVID-19: what awaits us in the future? Bulletin of Emergency and Reconstructive Surgery. 2021; 6(1): 47–55 [In Russian].
17. Alarcon-Rodrigues J., Fernandez-Velilla M., Urena-Vacas A. et al. Radiological management and follow-up of post-COVID-19 patients. Radiologia. 2021; 63: 258–269.
18. Karmakar S., Sharma P., Harishkumar A., Rai D.K. PostCOVID-19 pulmonary fibrosis: report of two cases. EMJ Respir. 2021. DOI:10.33590/emjrespir/20-00270.
19. Speranskaya A.A., Novikova L.N., Baranova O.P., et al. Radiation diagnosis of COVID-19 in patients with interstitial lung diseases. Visualization in Medicine. 2021; 3(1): 3–9 [In Russian].
20. Strukov A.I., Solovyova I.P. Morphology of tuberculosis in modern conditions. 2nd ed. Moscow, Medicine. 1986; 119. [In Russian].
21. Huang W., Wu Q., Chen Z. et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect. 2021; 82(2): e5-7. DOI:10.1016/j.jinf.2020.09.027.
22. Samsonova M.V., Kontorschikov A.S., Cherniaev A.L. et al. Longterm pathological changes in lungs after COVID-19. Pulmonologiya. 2021;31(5):571-579. DOI:10.18093/0869-0189-2021-31-5-571-579 [In Russian].
23. Zou J-N., Sun L., Wang B-R. et al. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS ONE. 2021; 16(3): e0248957. DOI:10.1371/journal.pone.0248957.
24. Franco-Palacios D.J., Allenspach L., Stagner L. et al. A center experience with lung transplantation for COVID-19 ARDS. Respiratory Medicine Case Reports. 2022; 36: 101597. DOI:10.1016/j.rmcr.2022.101597
25. Lesnyak V.N., Anan’eva L.P., Koneva O.A. et al. Semiquantification image methods for assessing severity of scleroderma-associated interstitial lung disease according to computed tomography data. Russian Pulmonology. 2017; 27 (1): 41–50. DOI:10.18093/0869-0189-2017-27-1-41-50 [In Russian].
26. Zolotnitskaya V.P., Titova O.N., Kuzubova N.A. et al. Changes in pulmonary microcirculation after COVID-19. Pulmonologiya. 2021;31(5):588-597. DOI:10.18093/0869-0189-2021-31-5-588-597 [In Russian].
Review
For citations:
Vinokurov A.S., Yudin A.L. Irreversible Lung Transformation Resulting from Damage In COVID-19 — Discourses and Examples of CT Images. The Russian Archives of Internal Medicine. 2022;12(5):370-379. https://doi.org/10.20514/2226-6704-2022-12-5-370-379
Views:
1233
Email this article 